Martien P M Caspers
Overview
Explore the profile of Martien P M Caspers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Jong J, Caspers M, Dulos R, Snabel J, van der Hoek M, van der Leij F, et al.
Geroscience
. 2024 Dec;
PMID: 39627572
Frailty is characterized by loss of physical function and is preferably diagnosed at an early stage (e.g., during pre-frailty). Unfortunately, sensitive tools that can aid early detection are lacking. Blood-based...
2.
Inia J, Attema J, de Ruiter C, Menke A, Caspers M, Verschuren L, et al.
FASEB J
. 2024 Oct;
38(20):e70087.
PMID: 39463193
Fibroblast growth factor 21 (FGF21) is a promising target for treatment of obesity-associated diseases including metabolic dysfunction-associated steatohepatitis (MASH) and atherosclerosis. We evaluated the effects of the bispecific anti-FGF21-β klotho...
3.
Venhorst J, Hanemaaijer R, Dulos R, Caspers M, Toet K, Attema J, et al.
Front Pharmacol
. 2024 Oct;
15:1442752.
PMID: 39399467
An target discovery pipeline was developed by including a directional and weighted molecular disease network for metabolic dysfunction-associated steatohepatitis (MASH)-induced liver fibrosis. This approach integrates text mining, network biology, and...
4.
Gonzalez Hernandez M, Verschuren L, Caspers M, Morrison M, Venhorst J, van den Berg J, et al.
Sci Rep
. 2024 Oct;
14(1):23362.
PMID: 39375498
The incidence of MASLD and MASH-associated fibrosis is rapidly increasing worldwide. Drug therapy is hampered by large patient variability and partial representation of human MASH fibrosis in preclinical models. Here,...
5.
Verschuren L, Mak A, van Koppen A, Ozsezen S, Difrancesco S, Caspers M, et al.
Nat Commun
. 2024 May;
15(1):4564.
PMID: 38811591
Accurate non-invasive biomarkers to diagnose metabolic dysfunction-associated steatotic liver disease (MASLD)-related fibrosis are urgently needed. This study applies a translational approach to develop a blood-based biomarker panel for fibrosis detection...
6.
Eveleens Maarse B, Eggink H, Warnke I, Bijlsma S, van den Broek T, Oosterman J, et al.
Nutr Metab Cardiovasc Dis
. 2024 Mar;
34(6):1416-1426.
PMID: 38499450
Background And Aims: The gut microbiome exerts important roles in health, e.g., functions in metabolism and immunology. These functions are often exerted via short-chain fatty acid (SCFA) production by gut...
7.
de Jong J, Caspers M, Worms N, Keijzer N, Kleemann R, Menke A, et al.
Geroscience
. 2024 Jan;
46(3):3341-3360.
PMID: 38265577
Muscle-aging drives sarcopenia and is a major public health issue. Mice are frequently used as a model for human muscle-aging, however, research investigating their translational value is limited. In addition,...
8.
Seidel F, Fluiter K, Kleemann R, Worms N, van Nieuwkoop A, Caspers M, et al.
Front Cell Neurosci
. 2023 Aug;
17:1267913.
PMID: 37614912
[This corrects the article DOI: 10.3389/fncel.2023.1205261.].
9.
Seidel F, Fluiter K, Kleemann R, Worms N, van Nieuwkoop A, Caspers M, et al.
Front Cell Neurosci
. 2023 Jul;
17:1205261.
PMID: 37457817
Introduction: Obesity has been linked to vascular dysfunction, cognitive impairment and neurodegenerative diseases. However, experimental models that recapitulate brain pathology in relation to obesity and vascular dysfunction are still lacking....
10.
de Jong J, Verschuren L, Caspers M, van der Hoek M, van der Leij F, Kleemann R, et al.
Biol Sex Differ
. 2023 Jul;
14(1):45.
PMID: 37430322
Background: Physical weakness is a key component of frailty, and is highly prevalent in older adults. While females have a higher prevalence and earlier onset, sex differences in the development...